Superworth

Supernus Pharmaceuticals EV/EBIT SUPN

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2015.

Today, Oct 23, 2026
n/m
an operating loss
Last meaningful
40.5×
Oct 2025
10-year median
14.6×
10-year range
5.8× to 81.6×
Peer median
10.5×

Supernus Pharmaceuticals has no meaningful EV/EBIT today: it made an operating loss of $130.5M over the last twelve months.

It was last meaningful in Oct 2025, at 40.5×.

On the days it had one over the last ten years, its median was 14.6×, from 5.8× in Mar 2020 to 81.6× in Sep 2023.

EV/EBIT over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
202540.5×15.9×40.5×
202450.9×44.6×57.6×
202347.3×38.7×81.6×
202210.4×10.4×12.7×
202111.1×7.9×12.7×
20208.1×5.8×9.2×
20198.9×8.2×15.0×
201812.5×12.0×28.4×
201724.0×22.3×44.5×
201638.3×26.5×45.3×
201533.2×32.4×77.9×

Against its peers

Companies in Drug Manufacturers - General nearest Supernus Pharmaceuticals' size, closest first, today.

CompanyEV/EBIT
SUPNSupernus Pharmaceuticalsn/m
PBHPrestige Consumer Healthcare14.5×
HRMYHarmony Biosciences6.9×
NRIXNurix Therapeutics7.1×
ANIPANI Pharmaceuticals10.5×
PAHCPhibro Animal Health11.7×
OGNOrganon9.5×
LQDALiquidia21.7×
ANABAnaptysbion/m
PCRXPacira BioSciences7.6×
ARQTArcutis Biotherapeutics111×
Peer median10.5×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Supernus Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.